A detailed history of Bellevue Group Ag transactions in Argenx Se stock. As of the latest transaction made, Bellevue Group Ag holds 632,829 shares of ARGX stock, worth $357 Million. This represents 5.78% of its overall portfolio holdings.

Number of Shares
632,829
Previous 691,874 8.53%
Holding current value
$357 Million
Previous $298 Million 15.35%
% of portfolio
5.78%
Previous 4.98%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$434.22 - $551.9 $25.6 Million - $32.6 Million
-59,045 Reduced 8.53%
632,829 $343 Million
Q2 2024

Aug 14, 2024

SELL
$356.01 - $451.55 $42.4 Million - $53.8 Million
-119,142 Reduced 14.69%
691,874 $298 Million
Q1 2024

May 15, 2024

SELL
$356.95 - $413.29 $20.8 Million - $24.1 Million
-58,192 Reduced 6.69%
811,016 $319 Million
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $14.3 Million - $21.4 Million
-42,322 Reduced 4.64%
869,208 $331 Million
Q3 2023

Nov 14, 2023

SELL
$369.35 - $548.43 $4.34 Million - $6.45 Million
-11,754 Reduced 1.27%
911,530 $448 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $13.1 Million - $15.4 Million
36,356 Added 4.1%
923,284 $360 Million
Q1 2023

May 15, 2023

SELL
$334.23 - $403.65 $8.08 Million - $9.76 Million
-24,172 Reduced 2.65%
886,928 $330 Million
Q4 2022

Feb 14, 2023

SELL
$342.17 - $402.31 $2.82 Million - $3.32 Million
-8,246 Reduced 0.9%
911,100 $345 Million
Q3 2022

Nov 14, 2022

SELL
$343.2 - $395.75 $4.96 Million - $5.72 Million
-14,457 Reduced 1.55%
919,346 $332 Million
Q2 2022

Aug 11, 2022

SELL
$269.58 - $378.88 $5.24 Million - $7.36 Million
-19,435 Reduced 2.04%
933,803 $350 Million
Q1 2022

May 13, 2022

SELL
$254.45 - $351.06 $11.1 Million - $15.4 Million
-43,800 Reduced 4.39%
953,238 $301 Million
Q4 2021

Feb 10, 2022

BUY
$272.01 - $353.03 $3.56 Million - $4.62 Million
13,100 Added 1.33%
997,038 $349 Million
Q3 2021

Nov 12, 2021

BUY
$295.0 - $350.58 $2.92 Million - $3.47 Million
9,900 Added 1.02%
983,938 $297 Million
Q2 2021

Aug 12, 2021

BUY
$257.11 - $319.92 $5.01 Million - $6.23 Million
19,484 Added 2.04%
974,038 $293 Million
Q1 2021

May 12, 2021

BUY
$268.3 - $380.31 $2.47 Million - $3.5 Million
9,206 Added 0.97%
954,554 $263 Million
Q4 2020

Feb 16, 2021

SELL
$248.13 - $308.36 $3.39 Million - $4.21 Million
-13,668 Reduced 1.43%
945,348 $278 Million
Q3 2020

Nov 16, 2020

BUY
$215.51 - $272.51 $1.08 Million - $1.36 Million
5,000 Added 0.52%
959,016 $252 Million
Q2 2020

Aug 13, 2020

SELL
$127.44 - $232.72 $2.61 Million - $4.77 Million
-20,488 Reduced 2.1%
954,016 $215 Million
Q1 2020

May 14, 2020

BUY
$108.83 - $165.23 $709,027 - $1.08 Million
6,515 Added 0.67%
974,504 $128 Million
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $559,597 - $862,102
-5,250 Reduced 0.54%
967,989 $156 Million
Q3 2019

Nov 14, 2019

BUY
$113.31 - $150.51 $3.24 Million - $4.3 Million
28,600 Added 3.03%
973,239 $110 Million
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $106 Million - $131 Million
924,739 Added 4646.93%
944,639 $134 Million
Q1 2019

May 15, 2019

BUY
$98.85 - $134.59 $721,605 - $982,507
7,300 Added 57.94%
19,900 $2.48 Million
Q4 2018

Feb 12, 2019

BUY
$63.81 - $109.82 $804,006 - $1.38 Million
12,600 New
12,600 $1.21 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.